Share: Facebook Twitter LinkedIn
Activity Provided By:


Myasthenia Gravis Research Highlights: AAN 2023

Access Activity

Overview / Abstract:

This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.

Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical trial data on these therapies were presented at the American Academy of Neurology Annual Meeting (AAN 2023) held in Boston, MA.

This CME program, hosted by Vera Bril, MD, of the University Hospital Network in Toronto, Canada, provides an overview of the latest clinical research presented at AAN 2023 focused on myasthenia gravis.


Jul 14, 2024


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

0.5 hours


American Academy of CME

Presenters / Authors / Faculty

Vera Bril, MD
University Hospital Network
Toronto, Canada

Sponsors / Supporters / Grant Providers

Argenx US and UCB

Keywords / Search Terms

CheckRare Rare Disease, Rare disorder, myasthenia gravis, rare autoimmune disease, neuromuscular junction, comorbidities, FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map